Welcome to our dedicated page for Imac Hldgs news (Ticker: BACK), a resource for investors and traders seeking the latest updates and insights on Imac Hldgs stock.
News and filings for IMAC Holdings, Inc. (BACK) highlight a company pivoting toward precision oncology through its subsidiary Ignite Proteomics LLC. Recent announcements describe the launch of Ignite, the transfer of a key Proprietary Laboratory Analyses (PLA) code for a proteomic breast cancer assay, and multiple clinical and research collaborations that showcase how the company applies Reverse Phase Protein Array (RPPA) technology to guide cancer treatment decisions.
Investors and healthcare observers following BACK news will encounter updates on Ignite’s CLIA‑certified and CAP‑accredited laboratory operations, as well as data presentations and peer‑reviewed publications. These include a case study in npj Precision Oncology demonstrating a complete response in metastatic triple‑negative breast cancer guided by proteomic analysis, and a British Journal of Cancer paper on functional activation of the AKT–mTOR signaling axis as a predictor of therapy response.
Company news also covers collaborations with institutions such as Inova Health and Vanderbilt University Medical Center. These projects involve profiling tumor and immune‑signaling pathways in gastrointestinal and breast cancers, using RPPA‑based assays to generate biomarker data for molecular tumor boards and immuno‑oncology research teams. Additional releases discuss the completed transfer of PLA code 0249U to Ignite Proteomics, positioning the assay within the Medicare Clinical Laboratory Fee Schedule and MolDx guidance.
Alongside scientific and clinical milestones, the news flow for IMAC Holdings includes Nasdaq notifications related to delayed Form 10‑Q filings and extensions to regain compliance with listing rules. By reviewing this news stream, readers can see how IMAC combines regulatory developments, financing disclosures, and proteomics‑focused clinical progress as it advances its stated goal of improving patient outcomes and personalized cancer care.
IMAC Holdings has appointed Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move aims to advance IMAC’s position in proteomics and precision medicine. Dr. Schwartz, with over 18 years of experience in radiotherapy and precision oncology, and Dr. Beitsch, with a background in surgical oncology and genomics, will contribute their expertise to guide IMAC's strategic initiatives. Their appointments align with the company's mission to revolutionize cancer treatment through proteomic technologies.
IMAC Holdings announced a major leadership transition, appointing Faith Zaslavsky as CEO, succeeding Jeff Ervin. This move aims to drive forward its newly acquired assets in the proteomics and precision medicine industry.
Zaslavsky brings 23 years of experience in the genomic space, having previously served as COO and CEO of Theralink Technologies and President of Oncology at Myriad Genetics. Her leadership is expected to enhance IMAC's mission of providing personalized treatment plans for cancer patients.
IMAC's RPPA technology, proven through clinical trials as a superior indicator for drug selection in breast cancer, is set to become an essential test for various cancers. The board now consists of three independent members following the resignation of co-founders Dr. Matt Wallis and Jeff Ervin, with Ervin continuing as a transition consultant.
IMAC Holdings, Inc. (NASDAQ: BACK) has acquired the assets of Theralink in a settlement agreement, excluding certain assets, to resolve outstanding debt issues. A merger with Theralink is no longer necessary, and a termination agreement has been entered into. The Registration Statement on Form S-4 has been withdrawn. The acquisition aims to continue the precision medicine business, focusing on advancements in breast cancer diagnostics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
IMAC Holdings reported a 14% annual revenue increase, totaling $16.1 million for FY 2022, up from $14.1 million in 2021. Patient revenue per visit rose to $105 compared to $84 in the previous year. Key initiatives include the completion of a Phase 1 clinical study for Parkinson’s disease and a merger agreement with Brain Scientific.
Despite the revenue growth, operating expenses rose significantly, leading to a higher operating loss of $18.2 million. Cash reserves dropped to $0.8 million from $7.1 million year-over-year due to a one-time $0.30/share impairment loss.
IMAC Holdings and Brain Scientific Announce Strategic Merger
On March 20, 2023, IMAC Holdings (BACK) and Brain Scientific (BRSFD) revealed a binding Letter of Intent for a merger-of-equals aimed at advancing solutions for neurological disorders like Parkinson's and Alzheimer's. The combined entity plans to leverage Brain Scientific's diagnostic technologies alongside IMAC's regenerative rehabilitation services. CEO Hassan Kotob of Brain Scientific will likely become Chairman and CEO of the newly formed company. The transaction is anticipated to close in summer 2023, pending shareholder approval and other conditions.